BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31
BIODESIX INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.40−0.26 (-1.10%)
Close on Oct 19, 2026
- Market cap
- $240.93M
- P/E (TTM)
- –
- Dividend yield
- –
BIODESIX INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostic Tests | $25.35M | $22.29M | $25.15M | $19.84M | $17.90M | $16.32M | $17.21M | $17.17M | $16.54M | $13.80M | $12.80M | $12.30M | 94.4% | +41.6% |
| Development Services | $1.51M | $3.26M | $3.61M | $1.93M | $2.12M | $1.64M | $3.22M | $983.00K | $1.39M | $1.02M | – | – | 5.6% | -28.7% |
| Services and Other | – | – | – | – | – | – | – | – | – | – | – | $1.19M | – | – |
| Biopharma Services and Other | – | – | – | – | – | – | – | $983.00K | $1.39M | $1.02M | $1.87M | $1.19M | – | – |
By region
From the segment and revenue-disaggregation notes of Biodesix's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.